Literature DB >> 28680312

Motor and Non-Motor Symptoms in Parkinson's Disease: Effects on Quality of Life.

Elif Gökçal1, Veysel Eren Gür1, Rabia Selvitop1, Gülsen Babacan Yildiz1, Talip Asil1.   

Abstract

INTRODUCTION: This study aimed to evaluate motor and non-motor symptoms in idiopathic Parkinson's disease (IPD) patients and to determine the self-reported influence of all existing symptoms on their quality of life (QoL).
METHODS: The sociodemographic and clinical characteristics, medical treatments, and Modified Hoehn and Yahr (mH&Y) scores of IPD patients without cognitive impairment were recorded. A survey questioning different motor and non-motor symptoms was administered to the patients. The patients were asked to rate their symptoms by number from the greatest influence to the least influence on their QoL. Subjects were divided into two groups: those suffering from IPD for ≤5 years (Group 1) and those suffering from IPD for >5 years (Group 2). These groups were compared in terms of sociodemographic and clinical characteristics, existing symptoms, and influences of these symptoms on their QoL.
RESULTS: There were 63 patients in Group 1 and 37 patients in Group 2. No statistically significant differences were detected between the groups with respect to sociodemographic characteristics or mH&Y scores. The most common motor symptoms in both of these groups were tremor and bradykinesia; meanwhile, the non-motor symptoms most frequently encountered in these groups were pain-cramps, constipation, and excessive daytime sleepiness (EDS). Again, while the symptoms that most greatly disturbed QoL in all patients were reported to be tremor and bradykinesia, the most disturbing non-motor symptom was frequent voiding/incontinence, which was a less common symptom. Pain-cramp, constipation, and EDS, which were the most frequent non-motor symptoms, were the symptoms that least disturbed QoL.
CONCLUSION: It is widely accepted that motor symptoms determine QoL in IPD. However, non-motor symptoms are seen during all phases of the disease. The impact of non-motor symptoms on the QoL of IPD patients remains substantial. Therefore, in addition to the well-known motor symptoms, non-motor symptoms, which may be overlooked during physical examination yet may profoundly impact QoL, should be questioned and treated appropriately to improve QoL in PD patients as much as possible.

Entities:  

Keywords:  Parkinson’s disease; motor symptoms; non-motor symptoms; quality of life

Year:  2016        PMID: 28680312      PMCID: PMC5491664          DOI: 10.5152/npa.2016.12758

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  25 in total

1.  Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: frequent but mild.

Authors:  Bernd Müller; Jan Petter Larsen; Tore Wentzel-Larsen; Geir Olve Skeie; Ole-Bjørn Tysnes
Journal:  Mov Disord       Date:  2010-10-05       Impact factor: 10.338

2.  Risk of dementia in Parkinson's disease: a community-based, prospective study.

Authors:  D Aarsland; K Andersen; J P Larsen; A Lolk; H Nielsen; P Kragh-Sørensen
Journal:  Neurology       Date:  2001-03-27       Impact factor: 9.910

3.  The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire.

Authors:  K Ray Chaudhuri; Cristina Prieto-Jurcynska; Yogini Naidu; Tanya Mitra; Belen Frades-Payo; Susanne Tluk; Anne Ruessmann; Per Odin; Graeme Macphee; Fabrizio Stocchi; William Ondo; Kapil Sethi; Anthony H V Schapira; Juan Carlos Martinez Castrillo; Pablo Martinez-Martin
Journal:  Mov Disord       Date:  2010-04-30       Impact factor: 10.338

4.  Fatigue in levodopa-naive subjects with Parkinson disease.

Authors:  G Schifitto; J H Friedman; D Oakes; L Shulman; C L Comella; K Marek; S Fahn
Journal:  Neurology       Date:  2008-08-12       Impact factor: 9.910

5.  Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis.

Authors:  I Arnulf; A M Bonnet; P Damier; B P Bejjani; D Seilhean; J P Derenne; Y Agid
Journal:  Neurology       Date:  2000-07-25       Impact factor: 9.910

6.  [Improving the quality of life and survival of cancer patients].

Authors:  J Bernheim
Journal:  Rev Med Liege       Date:  1984-02-01

7.  Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study.

Authors:  Sean S O'Sullivan; David R Williams; David A Gallagher; Luke A Massey; Laura Silveira-Moriyama; Andrew J Lees
Journal:  Mov Disord       Date:  2008-01       Impact factor: 10.338

Review 8.  Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions.

Authors:  D J Zgaljardic; N S Foldi; J C Borod
Journal:  J Neural Transm (Vienna)       Date:  2004-07-07       Impact factor: 3.575

9.  Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson's disease.

Authors:  Bernd Müller; Jörg Assmus; Karen Herlofson; Jan Petter Larsen; Ole-Bjørn Tysnes
Journal:  Parkinsonism Relat Disord       Date:  2013-08-02       Impact factor: 4.891

Review 10.  The prevalence of Parkinson's disease: a systematic review and meta-analysis.

Authors:  Tamara Pringsheim; Nathalie Jette; Alexandra Frolkis; Thomas D L Steeves
Journal:  Mov Disord       Date:  2014-06-28       Impact factor: 10.338

View more
  13 in total

Review 1.  PRE-084 as a tool to uncover potential therapeutic applications for selective sigma-1 receptor activation.

Authors:  Zeinab Y Motawe; Salma S Abdelmaboud; Javier Cuevas; Jerome W Breslin
Journal:  Int J Biochem Cell Biol       Date:  2020-07-12       Impact factor: 5.085

2.  DAT and TH expression marks human Parkinson's disease in peripheral immune cells.

Authors:  Adithya Gopinath; Phillip Mackie; Basil Hashimi; Anna Marie Buchanan; Aidan R Smith; Rachel Bouchard; Gerry Shaw; Martin Badov; Leila Saadatpour; Aryn Gittis; Adolfo Ramirez-Zamora; Michael S Okun; Wolfgang J Streit; Parastoo Hashemi; Habibeh Khoshbouei
Journal:  NPJ Parkinsons Dis       Date:  2022-06-07

3.  Profile of caregivers of Parkinson's disease patients and burden measured by Zarit Scale Analysis of potential burden-generating factors and their correlation with disease severity.

Authors:  Paulo Eduardo Mestrinelli Carrilho; Marcelo Alvarez Rodrigues; Brenda Camila Reck de Oliveira; Emanuelle Bianchi da Silva; Taline Alisson Artemis Lazzarin Silva; Leticia da Silva Schran; Marcia Mendes
Journal:  Dement Neuropsychol       Date:  2018 Jul-Sep

4.  Overexpression of Mitochondrial Ligases Reverses Rotenone-Induced Effects in a Drosophila Model of Parkinson's Disease.

Authors:  Bartosz Doktór; Milena Damulewicz; Elzbieta Pyza
Journal:  Front Neurosci       Date:  2019-02-14       Impact factor: 4.677

5.  Effects of robot-assisted gait training in patients with Parkinson's disease: study protocol for a randomized controlled trial.

Authors:  Min-Gu Kang; Seo Jung Yun; Hyun Iee Shin; Eunkyung Kim; Hyun Haeng Lee; Byung-Mo Oh; Han Gil Seo
Journal:  Trials       Date:  2019-01-07       Impact factor: 2.279

6.  SURINPARK: Safinamide for Urinary Symptoms in Parkinson's Disease.

Authors:  Ana Gómez-López; Arantxa Sánchez-Sánchez; Elena Natera-Villalba; Victoria Ros-Castelló; Álvaro Beltrán-Corbellini; Samira Fanjul-Arbós; Isabel Pareés Moreno; José Luis López-Sendon Moreno; Juan Carlos Martínez Castrillo; Araceli Alonso-Canovas
Journal:  Brain Sci       Date:  2021-01-06

7.  Heterogeneous digital biomarker integration out-performs patient self-reports in predicting Parkinson's disease.

Authors:  Kaiwen Deng; Yueming Li; Hanrui Zhang; Jian Wang; Roger L Albin; Yuanfang Guan
Journal:  Commun Biol       Date:  2022-01-17

8.  Complexity Measures of Voice Recordings as a Discriminative Tool for Parkinson's Disease.

Authors:  Rekha Viswanathan; Sridhar P Arjunan; Adrian Bingham; Beth Jelfs; Peter Kempster; Sanjay Raghav; Dinesh K Kumar
Journal:  Biosensors (Basel)       Date:  2019-12-20

Review 9.  New Avenues for Parkinson's Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota.

Authors:  Marina Lorente-Picón; Ariadna Laguna
Journal:  Biomolecules       Date:  2021-03-15

10.  Intraperitoneal Administration of Forskolin Reverses Motor Symptoms and Loss of Midbrain Dopamine Neurons in PINK1 Knockout Rats.

Authors:  Emmanuel Vazquez-Mayorga; Mariana Grigoruta; Raul Dagda; Bridget Martinez; Ruben K Dagda
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.